Stem Cell Therapy in Japan for American Patients: FDA vs Japan’s Framework, Costs, Travel and Follow-Up

Your treatment at a glance: visits, culture period, cost, language and follow-up

For an American patient, an initial course of autologous stem cell therapy at Cell Grand Clinic means two trips to Osaka of about three days each, about seven weeks apart, from JPY 2,970,000 per session tax included (approximately USD 19,800), with consultations in English directly with the physician and follow-up at 1, 3 and 6 months after you fly home.

The sections below explain each item in turn; the comparison of U.S. FDA rules with Japan’s regenerative medicine law comes near the end, just before the FAQ.

What is Cell Grand Clinic, and why do American patients choose it?

Cell Grand Clinic is a regenerative medicine clinic in Shinsaibashi, Osaka, Japan, that provides autologous adipose-derived stem cell therapy under 15 MHLW-notified plans, led by Dr. Yuichi Wakabayashi, MD, PhD — a Diplomate of the American Board of Regenerative Medicine who spent about three and a half years as a research fellow at the U.S. National Institutes of Health, has performed more than 3,000 stem cell treatments for patients from around 20 countries including the United States, and conducts every consultation in English himself.

For Americans used to being handed from a patient coordinator to a treating physician they meet on the day, the structure here is different: Dr. Wakabayashi reads your inquiry, assesses your records, performs the fat-tissue collection, administers the cells and conducts the follow-up at 1, 3 and 6 months. The cells are grown for you alone at a licensed cell processing centre, stopped at passage 3, checked by flow cytometry for the ISCT mesenchymal markers CD73, CD90 and CD105, with about 98% cell viability at release, and never pooled with another patient’s. And the clinical work is published: a knee osteoarthritis case treated with intra-articular cultured autologous ADSCs was reported in Cureus in 2026 (Kellgren–Lawrence grade 3, VAS pain 8 to 0 and JOA knee score 55 to 95 over about a year) — one documented case, not a guarantee, but outcomes that were written up and peer-reviewed rather than only advertised.

Cell Grand Clinic was named Top Regenerative Medicine Solution in APAC 2026 by Healthcare Business Review, is a member of Medical Excellence JAPAN, and Dr. Wakabayashi has been featured in The Wall Street Journal. The clinic is a five-minute walk from Shinsaibashi Station and about 50 minutes from Kansai International Airport (KIX), which has non-stop flights from Los Angeles and San Francisco of roughly 12 hours.

Stem Cell Therapy in Japan: Plans, Pricing & What to Expect Read Guide Cell Quality: The Key Factor That Impacts Stem Cell Therapy Outcomes Learn More

Which conditions do American patients ask about — and what does the evidence show?

The inquiries from the United States cluster around knee osteoarthritis, additional options alongside diabetes care, Alzheimer’s disease and age-related decline in function; for each, “stem cell therapy” is not one product, and evidence for a particular cell type, processing method and route of administration cannot be transferred to another.

Knee osteoarthritis. The most rigorous summary of randomised evidence is the 2025 Cochrane review in the Cochrane Database of Systematic Reviews, which pooled 25 trials and 1,341 participants. Compared with placebo injection at six months, pain averaged 4.5 out of 10 with placebo and was 1.2 points better with stem cell injection; function (0–100, lower is better) averaged 46.3 with placebo and was 14.2 points better with stem cells. The authors rated the certainty of this evidence as low and noted that the optimal preparation and dose of cells is unknown. In plain terms: a modest average benefit, real for some people and small for others, with no basis for promising that cartilage regrows or that a knee replacement will be avoided. Cell Grand Clinic’s published knee case used the same cell type and intra-articular route Cell Grand Clinic uses today, but it is a single case.

Diabetes. Mesenchymal cell therapy is not islet transplantation. Insulin independence reported after islet or stem-cell-derived islet transplants describes a different treatment. Mostly small trials of mesenchymal cells in type 2 diabetes — low to moderate certainty — have reported lower HbA1c and insulin requirements in some patients in the months after treatment, so the honest framing is support for glucose control assessed against your own baseline, not a cure. Keep taking whatever your U.S. physician has prescribed unless that physician changes it. Cell Grand Clinic’s diabetes plan is notified as PB5250050; the clinical detail is in the diabetes article below.

Alzheimer’s disease. Cell Grand Clinic’s plan for Alzheimer’s disease (PB5260030) was accepted by the MHLW in 2026 and is positioned as an early-stage and preventive option, not a replacement for the anti-amyloid antibodies now prescribed in the United States. The evidence base is early, and the dedicated article explains what can and cannot be claimed.

Anti-ageing and functional decline. The anti-ageing programme runs under the notified plan for frailty and pre-frailty (PB5250049), which defines what it is for: measurable loss of strength, stamina, recovery and everyday function. Bring a concrete concern — stairs, afternoon fatigue, recovery after exercise — that can be assessed before and after, rather than a request to “reverse age”.

Knee Osteoarthritis: A Non-Surgical Path with Stem Cells Read Article Stem Cell Therapy for Diabetes: A Regenerative Approach to Glycemic Control Learn More Is There a New Treatment for Alzheimer’s and Dementia? Stem Cell Therapy in Japan Read the Guide Reverse Aging: How Stem Cell IV Therapy Actually Works Learn How

How does the online consultation work from the United States?

Before you book anything, Cell Grand Clinic offers a 60-minute online video consultation with Dr. Wakabayashi in English for JPY 55,000 per person (about USD 370), credited in full toward treatment if you proceed; you receive an assessment of suitability, a proposed plan and an individual written quotation, with no obligation to go ahead.

The consultation runs on the records you send beforehand, so the preparation matters more than the call. For a knee: how long pain has limited walking and stairs, previous injections or surgery, and any X-ray or MRI report. For diabetes: type, recent A1c and glucose logs, kidney function and your medication or insulin schedule. For cognitive concerns: diagnosis, imaging or cognitive test results and current medication. For functional decline: the specific problem, when it began and a recent physical. Use what you have; the physician will say what is missing. Because of the time difference — Osaka is 13–14 hours ahead of New York and 16–17 hours ahead of Los Angeles, depending on daylight saving time — consultations are scheduled to suit U.S. mornings or evenings.

Tell your primary care physician or specialist that you are considering treatment abroad. They will be managing your medication and any complication after you return, and their questions — “Is this suitable for me?”, “What are the alternatives?”, “What remains uncertain?”, “What would you measure to know whether it worked?” — are the questions to bring to the consultation.

Request the consultation through the online consultation page, by WhatsApp or by email at info@cellgrandclinic.com.

How many trips to Osaka does an American patient need?

An initial course with newly cultured cells means two trips to Osaka about seven weeks apart, and Cell Grand Clinic recommends planning about three days in Osaka for each: on the first trip, the consultation, blood screening and fat-tissue collection take about half a day; on the second trip, the administration of your cultured cells takes 60–90 minutes, followed by observation before you fly home.

Treat the table as a planning framework, not a guaranteed timetable (further sessions, if the physician recommends them, mean additional trips on the same pattern): extra tests, a change in your health or an adjustment to the plan can move dates, so confirm the schedule with Cell Grand Clinic before buying non-refundable tickets. U.S. passport holders can enter Japan visa-free for short-term stays of up to 90 days, which covers both trips; the separate “Visa for Medical Stay” is for longer or repeated stays and is not needed here. Non-stop flights to Kansai International Airport (KIX) operate from Los Angeles (Japan Airlines) and San Francisco (United), each about 12 hours, with one-stop options via Tokyo from most major U.S. cities; KIX to Cell Grand Clinic is about 50 minutes by train or car. Many American patients combine the second trip with a few days in Kyoto or Nara once the observation period is over — but plan the medical days first and the sightseeing around them.

What does stem cell therapy in Japan cost in U.S. dollars?

Cell Grand Clinic’s autologous stem cell therapy starts from JPY 2,970,000 — approximately USD 19,800 at current exchange rates — per session for 100 million cells, tax included; the cell count and number of sessions depend on your condition and are decided by the physician, and every patient receives an individual written quotation in Japanese yen.

The dollar figure is an estimate that moves with the exchange rate; the yen figure is fixed in your quotation, and payment is made in yen. What the fee includes is the part that matters for comparison: the physician consultation and eligibility screening on the first visit, blood tests including infectious-disease screening, fat-tissue collection under local anaesthesia, cell isolation and expansion at the licensed cell processing centre with the quality release described above, symptomatic care during the culture period (exosome or PRP on the first visit, according to your plan), administration on the second visit, and follow-up at 1, 3 and 6 months. Not included: flights, accommodation, travel insurance, visa fees and any additional tests or treatments not listed in your quotation.

Three practical checks for U.S. patients. First, this is elective, self-paid treatment abroad; U.S. health insurance and Medicare do not cover it, and whether any account you hold can be used for medical expenses abroad is a question for your plan administrator or tax adviser, not for a clinic. Second, ask Cell Grand Clinic in writing how rescheduling is handled and what happens if screening finds you unsuitable or the culture cannot proceed as planned. Third, when you compare quotations — including from same-day procedures offered in the United States or from clinics in Mexico and elsewhere — compare what is inside them: whether the cells are culture-expanded or same-day tissue, the cell count and viability at release, whether cells are cultured individually or pooled, the route, the number of sessions and the follow-up. The pricing page lists the inclusions in full.

Who will you actually talk to — language, consent and risks

American patients speak directly with Dr. Wakabayashi, who conducts the consultation, explains the treatment, obtains consent and answers follow-up messages in English himself; an English and a Mandarin Chinese interpreter are also on site, and patients who prefer another language should bring their own interpreter or ask in advance about arranging one at additional cost.

A shared language does not shorten the consent discussion. Before you agree to treatment, you should understand the expected benefit for your condition, what remains uncertain, the alternatives (including the ones available at home), the possible adverse effects and what Cell Grand Clinic will do if something goes wrong, and you should receive a copy of the consent information. The International Society for Stem Cell Research’s patient guidance at aboutstemcells.org is a good checklist of the questions to bring.

Your own cells do not make the treatment risk-free. Reported risks include pain, bruising or infection at the fat-collection site, transient fever or fatigue after infusion, allergic reaction and, rarely, thromboembolic events with intravenous administration. Treatment may not be available for patients with active cancer, HIV, active severe infection or other conditions judged unsuitable at screening. Outcomes vary by individual and depend on disease stage, comorbidities and the treatment protocol; specific decisions should be made in consultation with qualified medical professionals, including your physicians in the United States.

What happens after you fly home to the United States?

Follow-up with Dr. Wakabayashi takes place at about 1, 3 and 6 months after treatment by email or video, so the last things to settle before leaving Osaka are what will be measured, who records it and which situations belong with a doctor in the United States rather than a message to Osaka.

For a knee, agree on the yardsticks in advance: pain during a defined activity such as stairs or a 20-minute walk, and how far you can walk before stopping. For diabetes, glucose monitoring and every medication decision stay with your U.S. physician; share your A1c and any changes with Cell Grand Clinic at each follow-up point. For Alzheimer’s disease, cognitive testing should continue with your neurologist on the same instruments used before treatment. Before you leave Osaka, ask for a written summary of what was done and when, the cells and route used, any medication given, aftercare instructions and the review schedule, and keep a copy for your U.S. physician — continuity of care is one of the main safeguards the CDC’s Yellow Book recommends for anyone receiving medical care abroad.

Remote follow-up is not a substitute for local examination or emergency care. If you develop chest pain, shortness of breath, a sudden change in consciousness or any other acute symptom after returning — including during or after the long flight — seek immediate medical attention in the United States; do not wait for a reply from overseas.

Why do Americans travel to Japan for stem cell therapy?

Americans travel to Japan because the U.S. Food and Drug Administration regulates culture-expanded stem cells as biological drugs that require a biologics license or an investigational new drug application before they can be given to patients, whereas Japan regulates the same treatment under a separate law that allows licensed clinics to provide cultured autologous cells after committee review and notification to the Ministry of Health, Labour and Welfare.

The U.S. position is not ambiguous. Under FDA’s framework for human cells, tissues and cellular and tissue-based products (HCT/Ps), a product that is more than “minimally manipulated” — and expanding cells in culture is the textbook example — is regulated as a biologic under section 351 of the Public Health Service Act rather than as a lower-tier section 361 tissue product. In its 2018 warning to a company producing expanded adipose-derived cells, FDA explained that because the processing “involves more than minimal manipulation of the adipose tissue”, the product needed a valid biologics license or an IND to be distributed lawfully. The practical effect is that a U.S. clinic cannot legally culture your fat-derived cells for weeks and reinfuse them outside a registered clinical trial; what is available in the United States is largely same-day, minimally processed tissue, or enrolment in a trial.

Japan took a different path. The Act on the Safety of Regenerative Medicine (2014) created a notification system: each treatment plan must be reviewed by a certified special committee for regenerative medicine and then submitted to the Ministry of Health, Labour and Welfare (MHLW), and the cells must be processed at a licensed cell processing facility. Cultured autologous cells fall into the Act’s Type 2 category — a higher-tier risk classification within the Act, applicable to treatments using cultured cells from the patient’s own body. Cell Grand Clinic has 15 MHLW-notified regenerative medicine provision plans, covering autologous stem cell therapy, PRP, cultured fibroblast therapy and NK cell therapy.

Two sentences keep this honest. FDA does not review or approve treatments provided in Japan, and a Japanese notification is not an FDA approval or a marketing authorisation for a drug. Japan’s system tells you that the plan was reviewed, that the facility is licensed and that a physician is accountable. Whether the treatment is likely to help you is a separate question answered by the evidence for your condition and by a medical assessment of your case — which is why the process at Cell Grand Clinic starts with a consultation, not a booking.

The table sets the two systems side by side for the same cells. For an American reader, the useful takeaway is that “legal in Japan” and “approved by FDA” describe different things, and neither is a promise of results. When you compare clinics in Japan, ask for the notified plan number that covers your condition rather than accepting words such as “certified”, “licensed” or “government-approved” at face value.

Frequently asked questions from American patients

Is stem cell therapy at Cell Grand Clinic FDA approved?

FDA does not review or approve treatments provided in Japan. Cell Grand Clinic’s treatments are provided in Osaka under Japan’s Act on the Safety of Regenerative Medicine, through plans reviewed by a certified committee and notified to the MHLW. That is a different system from FDA approval, and it is not a claim of FDA approval.

Which is the best stem cell clinic in Japan for patients from the United States?

There is no official ranking. Judge a clinic by verifiable facts: the MHLW plan number for your condition, a licensed cell processing centre with individual (non-pooled) culture and released quality data, a physician who assesses you before you travel, published outcomes and direct English communication. Cell Grand Clinic in Osaka meets each of these — 15 notified plans, individual culture with quality release, an NIH-trained ABRM-certified physician with 3,000+ treatments who consults in English himself, and a case report in Cureus — and starts with a paid online consultation so suitability is decided before you fly.

Why can’t I get culture-expanded stem cells in the United States?

Because FDA regulates cells grown in culture as biologics that need a biologics license or an investigational new drug application. Outside registered clinical trials, U.S. clinics can generally offer only minimally manipulated, same-day tissue products, which are a different treatment from cultured cells.

Can I have the fat collected and the cells administered in one trip?

Not with newly cultured cells. Culture and quality testing take about seven weeks, so the standard pathway is two trips of about three days each: one for collection and one for administration and observation.

How much is it in U.S. dollars?

From JPY 2,970,000 per session for 100 million cells, tax included — approximately USD 19,800 depending on the exchange rate. The quotation is in yen and payment is in yen; the dollar amount you pay depends on the rate on the day and your card or bank’s charges.

Do I need a visa?

U.S. passport holders can enter Japan visa-free for short-term stays of up to 90 days, which covers both trips. Check the Ministry of Foreign Affairs of Japan’s current rules before each trip.

Will U.S. health insurance or Medicare cover this?

No. This is elective, self-paid treatment abroad. Whether any account you hold can be used for medical expenses abroad is a question for your plan administrator or tax adviser.

Is treatment with my own cells safe?

Autologous cells avoid rejection but do not remove every risk. Reported risks include pain, bruising or infection at the collection site, transient fever or fatigue after infusion, allergic reaction and, rarely, thromboembolic events with intravenous administration. The physician explains the risks that apply to you before you consent.

Start with a medical assessment, then decide whether Osaka is the right next step

Before deciding whether to travel from the United States, settle four things: the expected benefit for your condition, what remains uncertain, the practical arrangements for two trips and the total commitment in yen. Send Cell Grand Clinic your medical history and goals through the online consultation page, by WhatsApp or at info@cellgrandclinic.com, have Dr. Wakabayashi assess your case, and then decide — together with your physician at home — whether an in-person assessment in Osaka is the right next step.

References

1. U.S. Food and Drug Administration. FDA warns American CryoStem Corporation of significant deviations related to its unapproved stem cell products (press announcement, 4 January 2018). fda.gov
2. Ministry of Health, Labour and Welfare (Japan). Submission of regenerative medicine provision plans under the Act on the Safety of Regenerative Medicine. mhlw.go.jp
3. Whittle SL, Johnston RV, McDonald S, et al. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews 2025;(4):CD013342. doi:10.1002/14651858.CD013342.pub2
4. Wakabayashi Y. Symptomatic improvement following intra-articular injection of cultured autologous adipose-derived mesenchymal stem cells in Kellgren-Lawrence grade 3 knee osteoarthritis: a case report with one-year follow-up. Cureus 2026;18(8):e113830. doi:10.7759/cureus.113830
5. International Society for Stem Cell Research. Nine things to know about stem cell treatments. aboutstemcells.org
6. Ministry of Foreign Affairs of Japan. Exemption of visa (short-term stay). mofa.go.jp
7. Centers for Disease Control and Prevention. Medical tourism. CDC Yellow Book. cdc.gov
8. Cell Grand Clinic. Stem cell therapy cost in Japan (pricing, inclusions, visit schedule and reported risks). cellgrandclinic.com/en/pricing

Medically reviewed by Yuichi Wakabayashi, MD, PhD · Last updated: September 2026

Updated: 2026.09.08